2021/04/30 ALA-1000 was granted by Intellectual Property Office of New Zealand.Patent No. 750367. Post author:alarpharm Post published:3 . 5 . 2021 Post category:Media releases You Might Also Like 2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022 2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020 2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021 2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021 2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 9 . 5 . 2022
2022/04/21 ALA-1000 Received notice of patent allowance from Intellectual Property Office of Singapore (IPOS), Application No. 11201901294Q. 21 . 4 . 2022
2020/08/21 Alar Pharmaceuticals Inc. Completes Pre-IND Meeting with US FDA for ALA-3000 24 . 8 . 2020
2021/03/10 Breaking the Cycle of Opioid Addiction: Alar Presents Positive Interim Results of Long-acting Buprenorphine Injectable (ALA-1000) in Opioid Dependent Patients 10 . 3 . 2021
2021/08/03 ALA-1000 Receive notice of patent allowance from Japan Patent Office (JPO), Application No. 特願2019-535434. 9 . 8 . 2021
2022/05/06 ALA-1000 Received notice of patent allowance from Intellectual Property Office of India , Application No. 201947006642 9 . 5 . 2022
